The history of the DNA-testing startup reads like a checklist of Silicon Valley clichés: founder squabbles, gobs of cash, a ...

Amgen's immunology drug results —The Novo Nordisk Senate hearing —Sanofi's soul-searching Read on to learn more.

The board of directors for 23andMe quit following disagreements over the CEO's plans to privatize the DNA testing company.

Once a hot $6 billion biotech company, 23andMe is now on the verge of collapse. What could happen to the DNA data of its 14 million customers?

All of 23andMe’s independent directors have resigned from its board in a rare move that marks the latest challenge for the ...

On Sept. 23, the board of directors at 23andMe, a prominent DNA testing company, announced their resignation following a series of disagreements with CEO Ann ...

If you are a holder of 23andMe, you are encouraged to submit your information at: On July 29, 2024, CEO Wojcicki submitted a non-binding proposal to 23andMe to acquire all shares of 23andMe that were ...

The pioneering DNA testing firm has been struggling to stay afloat financially despite ambitious ventures to provide health ...

With all seven independent directors resigning from 23andMe millions of customers are questioning how the company plans to ...

SUNNYVALE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co., (Nasdaq: ME), a leading human genetics and preventive health ...